Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and 2 bp insertion in exon 2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CDK17, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PCTAIRE2 also known as cyclin-dependent kinase 17 (CDK17) belongs to the large kinase family specifically involved in cell cycle regulation. It has a molecular mass of approximately 57 kDa and is mainly expressed in the brain and testis tissues. Like other members of the CDK family PCTAIRE2's activity is regulated by the binding of cyclins but it displays distinct substrate specificities. This protein structure includes a conserved kinase domain that suggests its role in phosphorylation and signal transduction processes.
Biological function summary
PCTAIRE2 functions in the modulation of neurodevelopmental processes and perhaps in the regulation of signal transmission in neurons. It may form complexes with various regulatory subunits affecting neuronal differentiation and outgrowth specifically in the brain. The presence of PCTAIRE2 in testis tissue indicates its potential role in reproductive biology though this function remains less understood compared to its neurological activities.
Pathways
PCTAIRE2 participates actively in pathways linked to neuronal signaling and development. The phosphorylation activity of PCTAIRE2 intertwines with proteins such as cyclins enabling the progression and regulation of cellular cycles particularly within neuronal cells. Moreover PCTAIRE2 links to pathways that include synaptic signaling interacting with related kinases that impact neuron structure and function though specific relationships to direct pathway members remain under ongoing investigation.
Researchers associate PCTAIRE2 with neurodegenerative conditions like Alzheimer's disease given its significant role in the brain. Its dysregulation could affect neuronal signaling pathways potentially leading to cognitive deficits. Additionally abnormalities in PCTAIRE2 expression relate to disorders of the male reproductive system though the precise mechanisms require further elucidation. Its interaction with key proteins such as tau protein may uncover further insights about its role in disease pathology where tauopathy plays a part.
